AstraZeneca Registers Phase III Clinical Trial for B7-H4 ADC, Hansoh/GSK Leads, Pfizer Halts Development
On November 17, 2025, the drug clinical trial registration and information disclosure platform showed that AstraZeneca registered the B7-H4 ADC Puxitatug Samrotecan (P-Sam, AZD8205) in a single-agent controlled physician’s choice chemotherapy treatment for patients with advanced/metastatic endometrial cancer (EC) that selectively expresses B7-H4 (≥25% tumor cell expression) and has progressed during or after platinum-based chemotherapy … Read more